Online inquiry

IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10112MR)

This product GTTS-WQ10112MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10112MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13846MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ10719MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ4446MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ1540MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ6287MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ7512MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ12611MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15790MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW